Clinical Applications of Immunofixation: Detection and Quantitation of Complement Activation

Overview

Journal J Clin Pathol

Specialty Pathology

Date 1980 Aug 1

PMID 6776155

Citations 12

Authors

J T Whicher

J Higginson

P G Riches

S Radford

Affiliations

Soon will be listed here.

Abstract

The methods currently in use for the detection and quantitation of complement activation products are slow and time consuming. We describe a method utilising immunofixation after agarose or cellulose acetate membrane electrophoresis which allows large batches of samples to be screened rapidly for the presence of activation products of C3 and factor B. Further, after immunofixation on agarose the conversion product may be quantitated by densitometry. This method gives similar results to those obtained by crossed immunoelectrophoresis. Using both this technique and crossed immunoelectrophoresis we have been able to confirm that C4 activation occurs during electrophoresis in the absence of EDTA and that in the presence of EDTA it is not demonstrable even in patients with active immune complex disease.

Citing Articles

A Flow Cytometry-Based Assay for the Measurement of Total Complement Activity in the Serum and Clinical Practice.

Ding X, Li S, Liu H Dis Markers. 2022; 2022:4532511.

PMID: 35047094 PMC: 8763518. DOI: 10.1155/2022/4532511.

Complement-mediated serum sensitivity among spirochetes that cause Lyme disease.

van Dam A, Oei A, Jaspars R, Fijen C, Wilske B, Spanjaard L Infect Immun. 1997; 65(4):1228-36.

PMID: 9119456 PMC: 175122. DOI: 10.1128/iai.65.4.1228-1236.1997.

Complement activation and complement control proteins in acute pancreatitis.

Whicher J, Barnes M, Brown A, Cooper M, Read R, Walters G Gut. 1982; 23(11):944-50.

PMID: 6922819 PMC: 1419797. DOI: 10.1136/gut.23.11.944.

Clinical application of a new nephelometric technique to measure complement activation.

Vergani D, Bevis L, Nasaruddin B, Mieli-Vergani G, TEE D J Clin Pathol. 1983; 36(7):793-7.

PMID: 6602812 PMC: 498390. DOI: 10.1136/jcp.36.7.793.

Activation of the alternative pathway of complement by monosodium urate monohydrate crystals and other inflammatory particles.

Doherty M, Whicher J, Dieppe P Ann Rheum Dis. 1983; 42(3):285-91.

PMID: 6407405 PMC: 1001133. DOI: 10.1136/ard.42.3.285.

References

Kohn J . A multi-sample applicator for zone electrophoresis. Clin Chim Acta. 1967; 18(1):65-8. DOI: 10.1016/0009-8981(67)90247-1. View

Rosenfeld S, Ruddy S, Austen K . Structural polymorphism of the fourth component of human complement. J Clin Invest. 1969; 48(12):2283-92. PMC: 297485. DOI: 10.1172/JCI106194. View

Alper C, Johnson A . Immunofixation electrophoresis: a technique for the study of protein polymorphism. Vox Sang. 1969; 17(5):445-52. DOI: 10.1111/j.1423-0410.1969.tb00414.x. View

Alper C, BOENISCH T, Watson L . Genetic polymorphism in human glycine-rich beta-glycoprotein. J Exp Med. 1972; 135(1):68-80. PMC: 2139116. DOI: 10.1084/jem.135.1.68. View

Sjoholm A, LAURELL A . Conversion of the fourth complement component studied by crossed immunoelectrophoresis. Clin Exp Immunol. 1973; 14(4):515-29. PMC: 1553814. View

Jordan R, Day N, Luckasen J, GOOD R . Complement activation in pemphigus vulgaris blister fluid. Clin Exp Immunol. 1973; 15(1):53-63. PMC: 1553867. View

Molenaar J, Muller M, Engelfriet C, Pondman K . Changes in antigenic properties of human C3 upon activation and conversion by trypsin. J Immunol. 1974; 112(4):1444-51. View

Perrin L, Lambert P, MIESCHER P . Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis. J Clin Invest. 1975; 56(1):165-76. PMC: 436567. DOI: 10.1172/JCI108065. View

Teisberg P . In vivo activation of C3 revealed by crossed immunoelectrophoresis as a parameter of immunological activity in disease. Clin Chim Acta. 1975; 62(1):35-41. DOI: 10.1016/0009-8981(75)90277-6. View

10.

Nicolson I, Ashby P, Johnson N, Versey J, Slater L . Boomslang bite with haemorrhage and activation of complement by the alternate pathway. Clin Exp Immunol. 1974; 16(2):295-300. PMC: 1553922. View

11.

Arroyave C, Tan E . Detection of complement activation by counterimmunoelectrophoresis (CIE). J Immunol Methods. 1976; 13(2):101-12. DOI: 10.1016/0022-1759(76)90148-4. View

12.

Buffone G, Lewis S . Effect of analytical factors on immunochemical reference limits for complement component C3 in serum of a reference pediatric population. Clin Chem. 1977; 23(6):994-9. View

13.

Fearon D, Austen K . Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins. J Exp Med. 1977; 146(1):22-33. PMC: 2180739. DOI: 10.1084/jem.146.1.22. View

14.

Whicher J . The value of complement assays in clinical chemistry. Clin Chem. 1978; 24(1):7-22. View

15.

Mauff G, Bender K, Fischer B . Genetic polymorphism of the fourth component of human complement. Vox Sang. 1978; 34(5):296-301. DOI: 10.1111/j.1423-0410.1978.tb02485.x. View

16.

Shadforth M, McNaughton D . Examination of complement C3 metabolism in rheumatoid arthritis using 2-dimensional immunoelectrophoresis. Ann Rheum Dis. 1978; 37(1):18-23. PMC: 1000182. DOI: 10.1136/ard.37.1.18. View

17.

Scharfstein J, Ferreira A, Gigli I, NUSSENZWEIG V . Human C4-binding protein. I. Isolation and characterization. J Exp Med. 1978; 148(1):207-22. PMC: 2184907. DOI: 10.1084/jem.148.1.207. View

18.

Fujita T, Gigli I, NUSSENZWEIG V . Human C4-binding protein. II. Role in proteolysis of C4b by C3b-inactivator. J Exp Med. 1978; 148(4):1044-51. PMC: 2185026. DOI: 10.1084/jem.148.4.1044. View